-
1
-
-
0027343763
-
Strategies for prevention of anthracycline cardiotoxicity
-
Basser R.L., Green M.D. Strategies for prevention of anthracycline cardiotoxicity. Cancer Treat. Rev. 19:1993;55-77.
-
(1993)
Cancer Treat. Rev.
, vol.19
, pp. 55-77
-
-
Basser, R.L.1
Green, M.D.2
-
2
-
-
0027169157
-
Cardioprotection by ICRF-187 against high dose anthracycline toxicity in children with malignant disease
-
Bu'Lock F.A., Gabriel H.M., Oakhill A., Mott M.G., Martin R.P. Cardioprotection by ICRF-187 against high dose anthracycline toxicity in children with malignant disease. Br. Heart J. 70:1993;185-188.
-
(1993)
Br. Heart J.
, vol.70
, pp. 185-188
-
-
Bu'Lock, F.A.1
Gabriel, H.M.2
Oakhill, A.3
Mott, M.G.4
Martin, R.P.5
-
3
-
-
0028959660
-
Ferrous ion strongly promotes the ring opening of the hydrolysis intermediates of the antioxidant cardioprotective agent dexrazoxane (ICRF-187)
-
Buss J.L., Hasinoff B.B. Ferrous ion strongly promotes the ring opening of the hydrolysis intermediates of the antioxidant cardioprotective agent dexrazoxane (ICRF-187). Arch. Biochem. Biophys. 317:1995;121-127.
-
(1995)
Arch. Biochem. Biophys.
, vol.317
, pp. 121-127
-
-
Buss, J.L.1
Hasinoff, B.B.2
-
4
-
-
0018915753
-
Enzymatic defenses of the mouse heart against reactive oxygen species
-
Doroshow J.H., Locker G.Y., Myers C.E. Enzymatic defenses of the mouse heart against reactive oxygen species. J. Clin. Invest. 65:1980;128-135.
-
(1980)
J. Clin. Invest.
, vol.65
, pp. 128-135
-
-
Doroshow, J.H.1
Locker, G.Y.2
Myers, C.E.3
-
5
-
-
0028329736
-
Cell cycle progression and chromosome segregation in mammalian cells cultured in the presence of the topoisomerase II inhibitors ICRF-187 and ICRF-159
-
Gorbsky G.J. Cell cycle progression and chromosome segregation in mammalian cells cultured in the presence of the topoisomerase II inhibitors ICRF-187 and ICRF-159. Cancer Res. 54:1994;1042-1048.
-
(1994)
Cancer Res.
, vol.54
, pp. 1042-1048
-
-
Gorbsky, G.J.1
-
6
-
-
0026459549
-
Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria
-
Gordeuk V.R., Thuma P.E., Brittenham G., McLaren C., Parry D., Backenstose A., Biemba G., Msiska R., Holmes L., McKinley E., Vargas L., Gilkeson R., Poltera A.A. Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria. N. Engl. J. Med. 327:1992;1473-1478.
-
(1992)
N. Engl. J. Med.
, vol.327
, pp. 1473-1478
-
-
Gordeuk, V.R.1
Thuma, P.E.2
Brittenham, G.3
McLaren, C.4
Parry, D.5
Backenstose, A.6
Biemba, G.7
Msiska, R.8
Holmes, L.9
McKinley, E.10
Vargas, L.11
Gilkeson, R.12
Poltera, A.A.13
-
7
-
-
0024573486
-
The interaction of the cardioprotective agent ICRF-187 (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane; Its hydrolysis product (ICRF-198), and other chelating agents with the Fe (III) and Cu (II) complexes of adriamycin
-
Hasinoff B.B. The interaction of the cardioprotective agent ICRF-187 (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane; its hydrolysis product (ICRF-198), and other chelating agents with the Fe (III) and Cu (II) complexes of adriamycin. Agents Action Suppl. 26:1989;378-385.
-
(1989)
Agents Action Suppl
, vol.26
, pp. 378-385
-
-
Hasinoff, B.B.1
-
8
-
-
0027517827
-
The removal of metal ions from transferrin, ferritin and ceruloplasmin by the cardioprotecitve agent ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl-propane] and its hydrolysis product ADR-925
-
Hasinoff B.B., Kala S.V. The removal of metal ions from transferrin, ferritin and ceruloplasmin by the cardioprotecitve agent ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl-propane] and its hydrolysis product ADR-925. Agents Actions Suppl. 39:1993;72-81.
-
(1993)
Agents Actions Suppl
, vol.39
, pp. 72-81
-
-
Hasinoff, B.B.1
Kala, S.V.2
-
9
-
-
0028217545
-
An HPLC and spectrometric study of the hydrolysis of ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane) and its open-ring hydrolysis intermediates
-
Hasinoff B.B. An HPLC and spectrometric study of the hydrolysis of ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane) and its open-ring hydrolysis intermediates. Int. J. Pharmacol. 107:1994;67-76.
-
(1994)
Int. J. Pharmacol.
, vol.107
, pp. 67-76
-
-
Hasinoff, B.B.1
-
10
-
-
0026636441
-
Free radicals, antioxidants and human disease. Where are we now
-
Halliwell B., Gutteridge J.M.C., Cross C.E. Free radicals, antioxidants and human disease. Where are we now. J. Lab. Clin. Med. 119:1992;598-620.
-
(1992)
J. Lab. Clin. Med.
, vol.119
, pp. 598-620
-
-
Halliwell, B.1
Gutteridge, J.M.C.2
Cross, C.E.3
-
11
-
-
0029758487
-
Molecular control of vertebrate iron metabolism: MRNA based regulatory circuits operated by iron, nitric oxide and oxidative stress
-
Hentze M.W., Kühn L.C. Molecular control of vertebrate iron metabolism. mRNA based regulatory circuits operated by iron, nitric oxide and oxidative stress Proc Natl Acad Sci USA. 93:1996;8175-8182.
-
(1996)
Proc Natl Acad Sci USA
, vol.93
, pp. 8175-8182
-
-
Hentze, M.W.1
Kühn, L.C.2
-
12
-
-
0019518585
-
Reduction of chronic doxirubicin cardiotoxicity in dogs by pretreatment with (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187)
-
Herman E.H., Ferrans V.J. Reduction of chronic doxirubicin cardiotoxicity in dogs by pretreatment with (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187). Cancer Res. 41:1981;3436-3440.
-
(1981)
Cancer Res.
, vol.41
, pp. 3436-3440
-
-
Herman, E.H.1
Ferrans, V.J.2
-
13
-
-
0028080144
-
Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats
-
Herman E.H., Zhang J., Ferrans V.J. Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats. Cancer Chemother. Pharamcol. 35:1994;93-100.
-
(1994)
Cancer Chemother. Pharamcol.
, vol.35
, pp. 93-100
-
-
Herman, E.H.1
Zhang, J.2
Ferrans, V.J.3
-
14
-
-
0027661677
-
Anthracycline toxicity is potentiated by iron and inhibited by deferoxamine. Studies in rat heart cells in culture
-
Hershko C., Link G., Tzahor A., Kaltwasser J.P., Athias P., Grynberg A., Pinson A. Anthracycline toxicity is potentiated by iron and inhibited by deferoxamine. Studies in rat heart cells in culture. J. Lab. Clin. Med. 122:1993;245-251.
-
(1993)
J. Lab. Clin. Med.
, vol.122
, pp. 245-251
-
-
Hershko, C.1
Link, G.2
Tzahor, A.3
Kaltwasser, J.P.4
Athias, P.5
Grynberg, A.6
Pinson, A.7
-
15
-
-
0029891617
-
ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumours
-
Holm B., Jensen P.B., Sehested M. ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumours. Cancer Chemother. Pharmacol. 38:1996;203-209.
-
(1996)
Cancer Chemother. Pharmacol.
, vol.38
, pp. 203-209
-
-
Holm, B.1
Jensen, P.B.2
Sehested, M.3
-
16
-
-
0028913032
-
A phase II trial of cardioprotection with cardioxane (ICRF-187) in patients with advanced breast cancer receiving fluoruracil, doxorubicin and cyclophosphamide
-
Kolaric K., Bradmante V., Cervek J., Cieslinska A., Cisarz-Filipcak E., Denisov L.E., Donat D., Drosik K., Gershanovic M., Hudziec P. A phase II trial of cardioprotection with cardioxane (ICRF-187) in patients with advanced breast cancer receiving fluoruracil, doxorubicin and cyclophosphamide. Oncology. 52:1995;251-255.
-
(1995)
Oncology
, vol.52
, pp. 251-255
-
-
Kolaric, K.1
Bradmante, V.2
Cervek, J.3
Cieslinska, A.4
Cisarz-Filipcak, E.5
Denisov, L.E.6
Donat, D.7
Drosik, K.8
Gershanovic, M.9
Hudziec, P.10
-
17
-
-
0021259518
-
Deferoxamine: A reversible S-phase inhibitor of human lymphocyte proliferation
-
Lederman H.M., Cohen A., Lee J.W.J., Freedman M., Gelfand E.W. Deferoxamine. a reversible S-phase inhibitor of human lymphocyte proliferation Blood. 64:1984;748-753.
-
(1984)
Blood
, vol.64
, pp. 748-753
-
-
Lederman, H.M.1
Cohen, A.2
Lee, J.W.J.3
Freedman, M.4
Gelfand, E.W.5
-
18
-
-
0029892535
-
Inhibition of anthracycline semiquinone formation by ICRF-187 (dexrazoxane) in cells
-
Malisza K.L., Hasinoff B.B. Inhibition of anthracycline semiquinone formation by ICRF-187 (dexrazoxane) in cells. Free Radic. Biol. Med. 20:1996;905-914.
-
(1996)
Free Radic. Biol. Med.
, vol.20
, pp. 905-914
-
-
Malisza, K.L.1
Hasinoff, B.B.2
-
19
-
-
0027502154
-
Iron sequestration by macrophages decreases the potential of extracellular hydroxyl radical formation
-
Olakanmi O., McGowan S.E., Hayek M.B., Britigan B.E. Iron sequestration by macrophages decreases the potential of extracellular hydroxyl radical formation. J Clin. Invest. 91:1993;889-899.
-
(1993)
J Clin. Invest.
, vol.91
, pp. 889-899
-
-
Olakanmi, O.1
McGowan, S.E.2
Hayek, M.B.3
Britigan, B.E.4
-
20
-
-
0030007125
-
Mapping of DNA topoisomerase II poisons (etoposide) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase catalytic cycle
-
Sehested M., Jensen P.B. Mapping of DNA topoisomerase II poisons (etoposide) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase catalytic cycle. Biochem. Pharmacol. 51:1996;879-886.
-
(1996)
Biochem. Pharmacol.
, vol.51
, pp. 879-886
-
-
Sehested, M.1
Jensen, P.B.2
-
21
-
-
0014938009
-
Mode of action of the cytostatic agent "iCRF-159"
-
Sharpe H.B.A., Field E.O., Hellmann K. Mode of action of the cytostatic agent "ICRF-159" Nature. 226:1970;524-526.
-
(1970)
Nature
, vol.226
, pp. 524-526
-
-
Sharpe, H.B.A.1
Field, E.O.2
Hellmann, K.3
-
22
-
-
0023693833
-
Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced toxicity in women with advanced breast cancer
-
Speyer J.L., Green M.D., Kramer E., Rey M., Sanger J., Ward C., Dubin N., Ferrans V., Stecy P., Zeleniuch-Jacquotte A., Wernz J., Frit F., Slater W., Blum R., Muggia F. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced toxicity in women with advanced breast cancer. N. Engl. J. Med. 319:1988;745-752.
-
(1988)
N. Engl. J. Med.
, vol.319
, pp. 745-752
-
-
Speyer, J.L.1
Green, M.D.2
Kramer, E.3
Rey, M.4
Sanger, J.5
Ward, C.6
Dubin, N.7
Ferrans, V.8
Stecy, P.9
Zeleniuch-Jacquotte, A.10
Wernz, J.11
Frit, F.12
Slater, W.13
Blum, R.14
Muggia, F.15
-
23
-
-
0026585672
-
ICRF-187 permits longer treatment with doxorubicin in women with breast cancer
-
Speyer J.L., Green M.D., Zeleniuch-Jacquette A., Wernz J.C., Rey M., Sanger J., Kramer E., Ferrans V., Hochster H., Meyers M., Blum R.H., Feit F., Attubato M., Burrows W., Muggia F.M. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J. Clin. Oncol. 10:1992;117-127.
-
(1992)
J. Clin. Oncol.
, vol.10
, pp. 117-127
-
-
Speyer, J.L.1
Green, M.D.2
Zeleniuch-Jacquette, A.3
Wernz, J.C.4
Rey, M.5
Sanger, J.6
Kramer, E.7
Ferrans, V.8
Hochster, H.9
Meyers, M.10
Blum, R.H.11
Feit, F.12
Attubato, M.13
Burrows, W.14
Muggia, F.M.15
-
24
-
-
0030904096
-
Cardioprotection with dexrazoxane for doxorubicin containing chemotherapy
-
Swain S.M., Whaley F.S., Gerber M.C., Weisberg S., York M., Spicer D., Jones S.E., Wadler S., Desai A., Vogel C., Speyer J.L., Mittelman A., Reddy S., Pendergrass K., Velez-Garcia V., Ewer M.S., Biachine J.R., Gams R.A. Cardioprotection with dexrazoxane for doxorubicin containing chemotherapy. J. Clin. Oncol. 15:1997;1318-1322.
-
(1997)
J. Clin. Oncol.
, vol.15
, pp. 1318-1322
-
-
Swain, S.M.1
Whaley, F.S.2
Gerber, M.C.3
Weisberg, S.4
York, M.5
Spicer, D.6
Jones, S.E.7
Wadler, S.8
Desai, A.9
Vogel, C.10
Speyer, J.L.11
Mittelman, A.12
Reddy, S.13
Pendergrass, K.14
Velez-Garcia, V.15
Ewer, M.S.16
Biachine, J.R.17
Gams, R.A.18
-
25
-
-
0026763513
-
In vitro effects of three iron chelators on mitogen activated lymphocytes: Identification of differences in their mechanism of action
-
Van Reyk D.M., Sarel S., Hunt N.H. In vitro effects of three iron chelators on mitogen activated lymphocytes. Identification of differences in their mechanism of action Int. J. Immunopharmacol. 14:1992;925-932.
-
(1992)
Int. J. Immunopharmacol.
, vol.14
, pp. 925-932
-
-
Van Reyk, D.M.1
Sarel, S.2
Hunt, N.H.3
-
26
-
-
10544231456
-
Multicenter randomized controlled clincal trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer
-
Venturini M., Michelotti A., DelMastro L., Gallo L., Carnino F., Garone O., Tibaldi C., Molea N., Bellina R.C., Pronzato P., Cyrus P., Vinke J., Testore F., Guelfi M., Lionettto R., Bruzzi P., Conte R.F., Rosso R. Multicenter randomized controlled clincal trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J. Clin. Oncol. 14:1996;3112-3120.
-
(1996)
J. Clin. Oncol.
, vol.14
, pp. 3112-3120
-
-
Venturini, M.1
Michelotti, A.2
Delmastro, L.3
Gallo, L.4
Carnino, F.5
Garone, O.6
Tibaldi, C.7
Molea, N.8
Bellina, R.C.9
Pronzato, P.10
Cyrus, P.11
Vinke, J.12
Testore, F.13
Guelfi, M.14
Lionettto, R.15
Bruzzi, P.16
Conte, R.F.17
Rosso, R.18
-
27
-
-
0030790471
-
Modulation of transferrin receptor expression by dexrazoxane (ICRF-187) via activation of iron regulatory protein
-
Weiss G., Kastner S., Brock J., Thaler J., Grunewald K. Modulation of transferrin receptor expression by dexrazoxane (ICRF-187) via activation of iron regulatory protein. Biochem. Pharmacol. 53:1997;1419-1424.
-
(1997)
Biochem. Pharmacol.
, vol.53
, pp. 1419-1424
-
-
Weiss, G.1
Kastner, S.2
Brock, J.3
Thaler, J.4
Grunewald, K.5
-
28
-
-
0029051815
-
Linkage of cellular immunity to iron metabolism
-
Weiss G., Wachter H., Fuchs D. Linkage of cellular immunity to iron metabolism. Immunol. Today. 16:1995;495-500.
-
(1995)
Immunol. Today
, vol.16
, pp. 495-500
-
-
Weiss, G.1
Wachter, H.2
Fuchs, D.3
-
29
-
-
9044233260
-
Randomized trial of cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin
-
Wexler L.H., Andrich M.P., Venzon D., Berg S.L., Weaver-McClure L., Chen C.C., Dilsizian V., Avila N., Jarosinski P., Balis F.M., Poplack D.G., Horowitz M.E. Randomized trial of cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J. Clin. Oncol. 14:1996;362-372.
-
(1996)
J. Clin. Oncol.
, vol.14
, pp. 362-372
-
-
Wexler, L.H.1
Andrich, M.P.2
Venzon, D.3
Berg, S.L.4
Weaver-Mcclure, L.5
Chen, C.C.6
Dilsizian, V.7
Avila, N.8
Jarosinski, P.9
Balis, F.M.10
Poplack, D.G.11
Horowitz, M.E.12
-
30
-
-
0026147704
-
Proliferation and cell cycle dependent differences in the expresion of the 170 kD and 180 kD forms of topoisomerase II in NIH-3T3 cells
-
Woessner R.D., Mattern M.R., Mirabelli C.K., Johnson R.K., Drake F.H. Proliferation and cell cycle dependent differences in the expresion of the 170 kD and 180 kD forms of topoisomerase II in NIH-3T3 cells. Cell Growth Diff. 2:1991;209-214.
-
(1991)
Cell Growth Diff.
, vol.2
, pp. 209-214
-
-
Woessner, R.D.1
Mattern, M.R.2
Mirabelli, C.K.3
Johnson, R.K.4
Drake, F.H.5
-
31
-
-
0022849760
-
2 reduction by iron complexes of adriamycin and daunorubicin: The importance of sidechain hydroxyl group
-
2 reduction by iron complexes of adriamycin and daunorubicin. the importance of sidechain hydroxyl group Biochem. Biophys. Acta. 884:1986;326-336.
-
(1986)
Biochem. Biophys. Acta.
, vol.884
, pp. 326-336
-
-
Zweier, J.L.1
Gianni, L.2
Muindi, J.3
Myers, C.E.4
|